GT Biopharma, Inc (GTBP)
NASDAQ: GTBP · IEX Real-Time Price · USD
2.75
+0.15 (5.77%)
Aug 12, 2022 4:00 PM EDT - Market closed
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|
| Revenue
|
0 | 0 | 0 | 0 | 0 | 0 | 0.03 | 0.06 |
| Revenue Growth (YoY)
|
- | - | - | - | - | - | -55.74% | - |
| Cost of Revenue
|
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.06 |
| Gross Profit
|
0 | 0 | 0 | 0 | 0 | 0 | 0.03 | 0 |
| Selling, General & Admin
|
47.92 | 6.28 | 9.79 | 12.49 | 134.5 | 8.4 | 7.95 | 2.4 |
| Research & Development
|
9.59 | 0.49 | 1.67 | 9.07 | 1.07 | 0.98 | 1 | 0 |
| Other Operating Expenses
|
0 | 0 | 4.6 | 228.52 | 0 | 0 | 0 | 0 |
| Operating Expenses
|
57.52 | 6.76 | 16.06 | 250.07 | 135.57 | 9.37 | 8.95 | 2.4 |
| Operating Income
|
-57.52 | -6.76 | -16.06 | -250.07 | -135.57 | -9.37 | -8.93 | -2.4 |
| Interest Expense / Income
|
0.72 | 3 | 2.13 | 9.12 | 8.6 | 6.56 | 17.04 | 5.15 |
| Other Expense / Income
|
-0.22 | 18.53 | 20.46 | 0 | 0 | -25.7 | -4.54 | 15.95 |
| Pretax Income
|
-58.01 | -28.3 | -38.65 | -259.19 | -144.17 | 9.77 | -21.43 | -23.49 |
| Net Income
|
-58.01 | -28.3 | -38.65 | -259.19 | -144.17 | 9.77 | -21.43 | -23.49 |
| Net Income Common
|
-58.01 | -28.3 | -38.65 | -259.19 | -144.17 | 9.77 | -21.43 | -23.49 |
| Shares Outstanding (Basic)
|
28 | 4 | 3 | 3 | 1 | 0 | 0 | 0 |
| Shares Outstanding (Diluted)
|
28 | 4 | 3 | 3 | 1 | 0 | 0 | 0 |
| Shares Change
|
542.06% | 29.59% | 14.50% | 199.60% | 20484.56% | -96.60% | 2.86% | - |
| EPS (Basic)
|
-2.06 | -6.45 | -0.01 | -87.72 | -146.20 | 2038.47 | -152.32 | -171.53 |
| EPS (Diluted)
|
-2.06 | -6.45 | -0.01 | -87.72 | -146.20 | 2038.47 | -152.32 | -171.53 |
| Free Cash Flow Per Share
|
-0.55 | -1.66 | -1.02 | -3.63 | -5.51 | -402.77 | -33.07 | - |
| Gross Margin
|
- | - | - | - | - | - | 100.00% | 6.60% |
| Operating Margin
|
- | - | - | - | - | - | -33063.00% | -3927.90% |
| Profit Margin
|
- | - | - | - | - | - | -79374.10% | -38506.60% |
| Free Cash Flow Margin
|
- | - | - | - | - | - | -17251.90% | - |
| EBITDA
|
-57.3 | -25.29 | -36.52 | -250.06 | -135.57 | 16.32 | -4.39 | - |
| EBITDA Margin
|
- | - | - | - | - | - | -16259.30% | - |
| Depreciation & Amortization
|
0 | 0 | 0 | 0.01 | 0 | 0 | 0 | - |
| EBIT
|
-57.3 | -25.29 | -36.52 | -250.07 | -135.57 | 16.32 | -4.39 | -18.34 |
| EBIT Margin
|
- | - | - | - | - | - | -16266.70% | -30070.50% |
Source: Financials are provided by
Nasdaq Data Link
and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).